Volume 8, Supplement 1 for health professionals who care for cancer patients 11 July 2005

Website access at http://www.bccancer.bc.ca/STUpdate/

I NSIDE THIS ISSUE

- Breaking News: Adjuvant Trastuzumab (Herceptin®) for Breast Cancer – New Policy
- Benefit Drug List Trastuzumab

- <u>List of New and Revised Protocols</u> New: BRAJACTT, BRAJTR, BRJACTTG, BRLAACDT
- <u>List of New and Revised Pre-Printed Orders</u> New: BRAJACTT, BRAJTR, BRJACTTG, BRLAACDT

FAX request form and IN TOUCH phone list are provided if additional information is needed.

BREAKING NEWS

ADJUVANT TRASTUZUMAB (HERCEPTIN®) FOR BREAST CANCER - NEW POLICY

The Provincial Systemic Therapy Program of the BC Cancer Agency is pleased to announce the funding of a new program on the use of adjuvant trastuzumab (Herceptin) for high risk HER2 overexpressing breast cancer. This new policy is based on the results of the clinical trials (Intergroup 9831, NSABP B31, HERA) reported at the American Society of Clinical Oncology meeting in May 2005. These showed a benefit in disease free survival and overall survival for the introduction of trastuzumab into adjuvant therapy for women with high risk HER2 overexpressing breast cancer. The new BCCA policy offers the following treatment options:

- 1. For newly diagnosed early breast cancer Doxorubicin/cyclophosphamide (AC) x 4 followed by paclitaxel/trastuzumab (Herceptin®) concurrently for 4 cycles followed by trastuzumab continued for a total of one year of trastuzumab therapy. (BRAJACTT, BRJACTTG)
- 2. For newly diagnosed locally advanced breast cancer AC x 4 followed by concurrent docetaxel/trastuzumab followed by trastuzumab continued for total of one year of trastuzumab therapy. (BRLAACDT)
- 3. For those already treated and completing in the past 6 months, or on treatment with AC-T,AC-D, CEF or FEC100 follow chemotherapy with trastuzumab x 1 year. (BRAJTR)

Patients who are not candidates for chemotherapy and are being treated with hormonal therapy only are not candidates for trastuzumab as there is no evidence at this time for the addition of trastuzumab to hormonal treatment in low risk disease.

More details of the eligibility, protocol, policy and preprinted physician's orders are available on the BC Cancer Agency web site (www.bccancer.bc.ca).

BENEFIT DRUG LIST

The following changes have been made to the Benefit Drug List effective 11 July 2005:

Drug	Indication	Benefit status
Docetaxel	 Treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel (Taxotere®) and trastuzumab (BRLAACDT) 	added as Class II
Paclitaxel	 Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (BRAJACTT) Adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (BRJACTTG) 	added as Class I
Trastuzumab	 Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (BRAJACTT) Adjuvant therapy for breast cancer using trastuzumab (Herceptin®) following the completion of chemotherapy (sequential) (BRAJTR) Adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (BRJACTTG) Treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel (Taxotere®) and trastuzumab (BRLAACDT) 	added as Class II

LIST OF NEW AND REVISED PROTOCOLS

The **BC Cancer Agency Protocol Summaries** are revised on a periodic basis. New and revised protocols for this month are listed below. Protocol codes for treatments requiring "Undesignated Indication" approval are prefixed with the letter **U**.

New protocols:

- **BRAJACTT** new: Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab
- **BRAJTR** new: Adjuvant therapy for breast cancer using trastuzumab (Herceptin®) following the completion of chemotherapy (sequential).
- **BRJACTTG** new: Adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab
- **BRLAACDT** new: Treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel (Taxotere®) and trastuzumab

LIST OF NEW AND REVISED PRE-PRINTED ORDERS

The **INDEX to BC Cancer Agency Pre-printed Orders** are revised on a periodic basis. New and revised pre-printed orders for this month are listed below.

New preprinted orders:

- BRAJACTT new: Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab
- **BRAJTR** new: Adjuvant therapy for breast cancer using trastuzumab (Herceptin®) following the completion of chemotherapy (sequential).
- **BRJACTTG** new: Adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab
- **BRLAACDT** new: Treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel (Taxotere®) and trastuzumab

WEBSITE RESOURCES

Reimbursement and Forms: The current Benefit Drug List, Class II forms and Undesignated Indication Application forms are available on the BC Cancer Agency website under Health Professionals Info, Chemotherapy Protocols, Frequently Used Forms (http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms.htm).

Cancer Drug Manual is available on the BC Cancer Agency website www.bccancer.bc.ca/cdm/.

Cancer Management Guidelines are available on the BC Cancer Agency website (http://www.bccancer.bc.ca/CaMgmtGuidelines/) under Health Professionals Info, Cancer Management Guidelines.

The Cancer Chemotherapy Protocols are available on the BC Cancer Agency website (www.bccancer.bc.ca/ChemoProtocols) under Health Professionals Info, Chemotherapy Protocols.

The Cancer Chemotherapy Pre-Printed Orders are available on the BC Cancer Agency website (www.bccancer.bc.ca/ChemoProtocols) under Health Professionals Info, Chemotherapy Protocols. Pre-Printed Orders are posted at the index page of each tumour site.

Provincial Systemic Therapy Program Policies are available on the BC Cancer Agency website (www.bccancer.bc.ca) under Health Professionals Info, Chemotherapy Protocols, Policies and Procedures.

The <u>Unconventional Cancer Therapies Manual</u> is available on the BC Cancer Agency website <u>www.bccancer.bc.ca</u> under Patient/Public Info, Unconventional Therapies.

EDITORIAL REVIEW BOARD

Mário de Lemos, MSc, PharmD (Editor)	Karen Janes, MSN	
Thanh Vu, PharmD (Assistant Editor)	Beth Morrison, MLS	
Cicely Bryce, MD	Jaya Venkatesh, MHA	
Johanna Den Duyf, MA	Susan Walisser, BSc (Pharm)	
	Gigi Concon (Editorial Assistant)	

In Touch	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC Cancer Agency	(604) 877-6000	Toll-Free 1-(800) 663-3333
Communities Oncology Network	Ext 2744	jvenkate@bccancer.bc.ca
Education Resource Nurse	Ext 2638	nursinged@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	ilundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 6277	Ikovacic@bccancer.bc.ca
Drug Information	Ext 6275	druginfo@bccancer.bc.ca
Library / Cancer Information	(604)-675-8003	requests@bccancer.bc.ca
OSCAR Hotline	1-888-355-0355	
Update Editor	Ext 2288	mdelemos@bccancer.bc.ca
Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888) 563-7773
Fraser Valley Centre (FVCC)	(604) 930-2098	Toll-Free 1-(800) 523-2885
Vancouver Centre (VCC)	(604) 877-6000	Toll-Free 1-(800) 663-3333
Vancouver Island Centre (VICC)	(250) 519-5500	Toll-Free 1-(800) 670-3322

BC CANCER AGENCY SYSTEMIC THERAPY UPDATE REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247
OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247
PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES